Trial Profile
Leucine-rich alpha-2 glycoprotein (LRG): as a biomarker to monitor the responses to biologics and apremilast in psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Biomarker; Pharmacodynamics
- 13 Jul 2018 New trial record
- 16 Jun 2018 Results assessing serum LRG for a biomarker to monitor the responses to biologics, presented at the 19th Annual Congress of the European League Against Rheumatism